880094-83-7

Basic information

• Product Name: 5-BROMO-3,4-DIHYDROQUINOLIN-2(1H)-ONE
• Synonyms: 5-BROMO-3,4-DIHYDROQUINOLIN-2(1H)-ONE;5-bromo-3,4-dihydro-2(1H)-Quinolinone;5-Bromo-3,4-dihydroquinolin-2(1H)
• CAS NO: 880094-83-7
• Molecular Formula: C9H8BrNO
• Molecular Weight: 226.07
• Mol File: 880094-83-7.mol

Chemical Properties

• Boiling Point: 372.4±42.0 °C(Predicted)
• Appearance: /
• Density: 1.559±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 14.02±0.20(Predicted)
• CAS DataBase Reference: 5-BROMO-3,4-DIHYDROQUINOLIN-2(1H)-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-3,4-DIHYDROQUINOLIN-2(1H)-ONE(880094-83-7)
• EPA Substance Registry System: 5-BROMO-3,4-DIHYDROQUINOLIN-2(1H)-ONE(880094-83-7)

Safety Data

• Hazardous Substances Data: 880094-83-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-BROMO-3,4-DIHYDROQUINOLIN-2(1H)-ONE is used as a building block for the synthesis of various biologically active molecules, playing a crucial role in the development of potential drug candidates. Its unique chemical properties and structure contribute to the creation of new pharmaceutical compounds and serve as a valuable tool for medicinal chemistry research. 5-BROMO-3,4-DIHYDROQUINOLIN-2(1H)-ONE's versatility in synthesis allows for the exploration of its potential in treating a range of medical conditions, making it an important asset in the advancement of pharmaceutical science.

Upstream product

• 15115-58-9 3-(2-bromophenyl)propionic acid 
• 75-75-2 methanesulfonic acid 
• 15115-60-3 4-bromo-2,3-dihydroinden-1-one 

Downstream Products

• 2446617-95-2 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroquinolin-2(1H)-one 
• 34591-83-8 5-hydroxy-1-methyl-3,4-dihydroquinolin-2(1H)-one 

Relevant articles and documents

Visible-Light Induced C(sp2)?H Amidation with an Aryl–Alkyl σ-Bond Relocation via Redox-Neutral Radical–Polar Crossover

We report an approach for the intramolecular C(sp2)?H amidation of N-acyloxyamides under photoredox conditions to produce δ-benzolactams with an aryl-alkyl σ-bond relocation. Computational studies on the designed reductive single electron transfer strategy led us to identify N-[3,5-bis(trifluoromethyl)benzoyl] group as the most effective amidyl radical precursor. Upon the formation of an azaspirocyclic radical intermediate by the selective ipso-addition with outcompeting an ortho-attack, radical–polar crossover was then rationalized to lead to the rearomative ring-expansion with preferential C?C bond migration.

Room Temperature Benzofused Lactam Synthesis Enabled by Cobalt(III)-Catalyzed C(sp2)?H Amidation

Benzofused lactams, especially indolin-2-one and dihydroquinolin-2-one are popular structural motives in durgs and natural products. Herein, we developed a room temperature and robust synthesis of benzofused lactams through cobalt(III)-catalyzed C(sp

INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN

Compounds and compositions for modulating fibroblast activation protein (FAP) are described. The compounds and compositions may find use as therapeutic agents for the treatment of diseases, including hyperproliferative diseases.

Focal adhesion kinase inhibitor and use

The invention belongs to the field of medicines, relates to a focal adhesion kinase inhibitor and use, in particular relates to a novel focal adhesion kinase inhibitor compound, or stereoisomers, geometric isomers, tautomers, oxynitrides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof, further relates to the use of the compound and pharmaceutical compositions as medicines, in particular the use of the compound and pharmaceutical compositions in manufacture of medicines for treatment or prevention of cancer, pulmonary hypertension, and pathological angiogenesis-related diseases.

Selective formation of γ-lactams via C-H amidation enabled by tailored iridium catalysts

Intramolecular insertion of met al nitrenes into carbon-hydrogen bonds to form γ-lactam rings has traditionally been hindered by competing isocyanate formation. We report the application of theory and mechanism studies to optimize a class of pentamethylcyclopentadienyl iridium(III) catalysts for suppression of this competing pathway. Modulation of the stereoelectronic properties of the auxiliary bidentate ligands to be more electron-donating was suggested by density functional theory calculations to lower the C-H insertion barrier favoring the desired reaction. These catalysts transform a wide range of 1,4,2-dioxazol-5-ones, carbonylnitrene precursors easily accessible from carboxylic acids, into the corresponding γ-lactams via sp3 and sp2 C-H amidation with exceptional selectivity. The power of this method was further demonstrated by the successful late-stage functionalization of amino acid derivatives and other bioactive molecules.

COMPOUNDS AND METHODS FOR TREATING CANCERS

Provided are carbazole and carbazole-like compounds (e.g., pyridoindole and pyrrolodipyridine compounds. The compounds can be used to selectively kill cancer cells.

ARYL HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS

Compounds of formula I: I (wherein variables A1, A2, B, m, n, J, X, R4, G1, G2, G3 and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatme

ARYL SPIROLACTAM CGRP RECEPTOR ANTAGONISTS

The present invention is directed to compounds of Formula (I): where variables A1, A2, B, J, K, m, n, R4, R5a, R5b, R5c and X are as defined herein useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.